Clinical trials: JC Virus Infection
Multiple Sclerosis
JC-Virus (JCV) Antibody Program
The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment.
- Trial name
- STRATIFY-1 (NCT01070823)
- Testing
- Tysabri® (natalizumab)
- Where
- 11 sites in United States
- Volunteers
- 1,096 people
- Sponsor
- Biogen
Infection
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- CHARMS (NCT02108522)
- Testing
- Multivirus Specific T cells
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- AlloVir
Adenovirus Infection, BK Virus Infection
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT05101213
- Testing
- Virus-specific Cytotoxic T-lymphocytes
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Sclerosis
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
The objective of the study is to estimate the prevalence of anti-JCV antibodies in multiple sclerosis (MS) participants.
- Trial name
- JEMS (NCT01185717)
- Volunteers
- 7,726 people
- Sponsor
- Biogen
Epstein-Barr Virus Infection, Cytomegalovirus Infections
TETRAVI Expanded Access Program
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the…
- Conditions
- Epstein-Barr Virus Infection, Cytomegalovirus Infections, Adenovirus Infection, BK Virus Infection
- Trial name
- NCT07104591
- Testing
- HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)
- Sponsor
- Baylor College of Medicine
Multiple Sclerosis
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Under the escalation treatment strategy when a patient displays breakthrough disease parameters under first line therapy, MS physicians are allowed by the EMEA to switch for Natalizumab (NTZ) or fingolimod (FGL).
- Trial name
- BEST-MS (NCT01981161)
- Testing
- biological samples and clinical data
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 307 people
- Sponsor
- University Hospital, Toulouse
PML, AIDS
Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome
This study will identify genetic factors associated with the development of progressive multifocal leukoencephalopathy (PML) in patients with acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT00342602
- Where
- 6 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Relapsing Multiple Sclerosis
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV)…
- Trial name
- STRATIFY-2 (NCT01070836)
- Testing
- natalizumab
- Where
- 478 sites in United States, Puerto Rico
- Volunteers
- 35,895 people
- Sponsor
- Biogen
Progressive Multifocal Leukoencephalopathy
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
The primary objective of the study was to explore whether mefloquine can delay or stop progression of progressive multifocal leukoencephalopathy (PML) as measured by JC virus (human polyomavirus or JCV) deoxyribonucleic acid…
- Trial name
- NCT00746941
- Testing
- mefloquine
- Where
- 12 sites in United States, Brazil and 3 more
- Volunteers
- 37 people
- Sponsor
- Biogen
Adenovirus Infection, BK Virus Infection
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT04693637)
- Testing
- Posoleucel (ALVR105)
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- AlloVir
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
Acquired Immunodeficiency Syndrome, BK Virus Infection
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus.
- Conditions
- Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection
- Trial name
- NCT02479698
- Testing
- Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Progressive Multifocal Leukoencephalopathy
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
This is a randomized, double-blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response…
- Trial name
- ASCEND-JC (NCT05541549)
- Testing
- CE-VST01-JC
- Volunteers
- 60 people
- Sponsor
- Cellevolve Bio Inc
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
JC Virus Reactivation in Multiple Sclerosis
JC virus is a benign virus which infects approximately up to 90% of the normal adult population. However, it may be reactivated in people who have a decreased immune function as in HIV infection, cancer, chemotherapy, transplant…
- Trial name
- JCV in MS (NCT02004444)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Beth Israel Deaconess Medical Center
Relapsing-Remitting Multiple Sclerosis
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
The primary objective of the study is to determine which baseline and yearly response factors (clinical and para clinical) predict overall disease-free status at Month 12 and Month 24, and clinical disease-free status in…
- Trial name
- STRIVE (NCT01485003)
- Testing
- natalizumab
- Where
- 44 sites in United States
- Volunteers
- 231 people
- Sponsor
- Biogen
Progressive Multifocal Leukoencephalopathy
Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
This is a continuation of our previous studies on Progressive Multifocal Leukoencephalopathy (PML). We will focus on the role of inflammation in PML, and define prognostic markers of disease evolution.
- Trial name
- NCT01132053
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Beth Israel Deaconess Medical Center
Progressive Multifocal Leukoencephalopathy, PML
Observational Study on Characteristics and Survival Correlates of Progressive Multifocal Leukoencephalopathy (PML) in Italy
The goal of this observational study is to learn about the features of Progressive Multifocal Leukoencephalopathy (PML) at the time of its diagnosis and the factors that may influence the outcome of persons with this disease.
- Trial name
- MI_PML (NCT06594614)
- Where
- Italy
- Volunteers
- 456 people
- Sponsor
- Scientific Institute San Raffaele